Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Quiroga-Varela

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|April 1, 2025
Luminex Multiplex Immunoassay for Proteomic Profiling of Cerebrospinal FluidJoana M Huertas-Pons, Ana Quiroga-Varela
Frontiers in Psychiatry|February 13, 2025
Assessment of clinical prognosis in autoimmune encephalitis: Girona scoreGary Álvarez Bravo, Giuseppe Guglielmini, Ana Quiroga Varela, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 25, 2020
[<sup>18</sup>F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degenerationTatiana Rodríguez-Chinchilla, Ana Quiroga-Varela, Francisco Molinet-Dronda, et al.
Frontiers in Psychology|May 4, 2026
Correction: Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factorsClàudia Coll-Martinez, Judit Salavedra-Pont, Maria Buxó, et al.
Frontiers in Psychology|September 8, 2023
Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factorsClàudia Coll-Martinez, Judit Salavedra-Pont, Maria Buxó, et al.
European Journal of Neurology|July 24, 2023
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case reportMarc Puig-Casadevall, Gary Álvarez-Bravo, Ana Quiroga Varela, et al.
Neurobiology of Disease|February 15, 2015
Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo studyFrancisco Molinet-Dronda, Belén Gago, Ana Quiroga-Varela, et al.
Parkinsonism & Related Disorders|December 28, 2019
Disrupted salience network dynamics in Parkinson's disease patients with impulse control disordersIrene Navalpotro-Gomez, Jinhee Kim, Pedro M Paz-Alonso, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 14, 2018
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective studyManuel Delgado-Alvarado, Rosalía Dacosta-Aguayo, Irene Navalpotro-Gómez, et al.
Psychopharmacology|July 4, 2020
Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian ratsHaritz Jiménez-Urbieta, Belén Gago, Ana Quiroga-Varela, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|April 1, 2025
Luminex Multiplex Immunoassay for Proteomic Profiling of Cerebrospinal FluidJoana M Huertas-Pons, Ana Quiroga-Varela
Frontiers in Psychiatry|February 13, 2025
Assessment of clinical prognosis in autoimmune encephalitis: Girona scoreGary Álvarez Bravo, Giuseppe Guglielmini, Ana Quiroga Varela, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 25, 2020
[<sup>18</sup>F]-DPA-714 PET as a specific in vivo marker of early microglial activation in a rat model of progressive dopaminergic degenerationTatiana Rodríguez-Chinchilla, Ana Quiroga-Varela, Francisco Molinet-Dronda, et al.
Frontiers in Psychology|May 4, 2026
Correction: Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factorsClàudia Coll-Martinez, Judit Salavedra-Pont, Maria Buxó, et al.
Frontiers in Psychology|September 8, 2023
Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factorsClàudia Coll-Martinez, Judit Salavedra-Pont, Maria Buxó, et al.
European Journal of Neurology|July 24, 2023
Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case reportMarc Puig-Casadevall, Gary Álvarez-Bravo, Ana Quiroga Varela, et al.
Neurobiology of Disease|February 15, 2015
Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo studyFrancisco Molinet-Dronda, Belén Gago, Ana Quiroga-Varela, et al.
Parkinsonism & Related Disorders|December 28, 2019
Disrupted salience network dynamics in Parkinson's disease patients with impulse control disordersIrene Navalpotro-Gomez, Jinhee Kim, Pedro M Paz-Alonso, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 14, 2018
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective studyManuel Delgado-Alvarado, Rosalía Dacosta-Aguayo, Irene Navalpotro-Gómez, et al.
Psychopharmacology|July 4, 2020
Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian ratsHaritz Jiménez-Urbieta, Belén Gago, Ana Quiroga-Varela, et al.
Pageof 4